{"nctId":"NCT00808444","briefTitle":"Primary Vaccination Study With a Pneumococcal Conjugate Vaccine in Healthy Children 6-12wks of Age","startDateStruct":{"date":"2009-01-05"},"conditions":["Infections, Streptococcal"],"count":466,"armGroups":[{"label":"Synflorix Clinical Lot & Infanrix Group","type":"EXPERIMENTAL","interventionNames":["Biological: Pneumococcal conjugate vaccine GSK1024850A (different lots)","Biological: Infanrix hexa","Biological: Infanrix-IPV/Hib","Biological: Rotarix"]},{"label":"Synflorix Commercial Lot Infanrix Group","type":"EXPERIMENTAL","interventionNames":["Biological: Pneumococcal conjugate vaccine GSK1024850A (different lots)","Biological: Infanrix hexa","Biological: Infanrix-IPV/Hib","Biological: Rotarix"]}],"interventions":[{"name":"Pneumococcal conjugate vaccine GSK1024850A (different lots)","otherNames":[]},{"name":"Infanrix hexa","otherNames":["DTPa-combined vaccine"]},{"name":"Infanrix-IPV/Hib","otherNames":["DTPa-combined vaccine"]},{"name":"Rotarix","otherNames":["HRV vaccine"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Male or female subjects between, and including 6-12 weeks of age at the time of the first vaccination.\n* Subjects for whom the investigator believes that their parent(s)/guardian(s) can and will comply with the requirements of the protocol.\n* Written or oral, signed or thumb-printed informed consent obtained from the parent(s)/guardian(s) of the child/ward.\n* Free of any known or suspected health problems (as established by medical history and clinical examination before entering into the study).\n* Born after a gestation period of \\>= 36 to \\<= 42 weeks.\n\nExclusion Criteria:\n\n* Use of any investigational or non-registered product (drug or vaccine) other than the study vaccines within 30 days preceding the first dose of the study vaccines, or planned use during the study period.\n* Concurrently participating in another clinical study, at any time during the study period.\n* Chronic administration (defined as more than 14 days) of immunosuppressants or other immune-modifying drugs since birth.\n* A family history of congenital or hereditary immunodeficiency.\n* Any confirmed or suspected immunosuppressive or immunodeficient condition based on medical history and physical examination.\n* Administration of immunoglobulins and/or any blood products since birth or planned administration during the study period (with the exception of hepatitis B immunoglobulins at birth).\n* Previous vaccination against diphtheria, tetanus, pertussis, poliomyelitis, hepatitis B, Haemophilus influenzae type b and/or Streptococcus pneumoniae (with the exception of vaccines where the first dose can be given within the first two weeks of life).\n* Planned administration/administration of a vaccine not foreseen by the study protocol during the period starting 30 days before each dose of vaccine and ending 7 days after Dose 1 and Dose 2 and 30 days after Dose 3.\n* History of, or intercurrent diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis, H. influenzae type b and rotavirus disease.\n* History of allergic disease or reactions likely to be exacerbated by any component of the vaccines.\n* History of any neurological disorders or seizures.\n* Major congenital defects or serious chronic illness.\n* Acute disease at the time of enrolment.\n* Gastroenteritis within 7 days preceding the study vaccine administration.\n* Any clinically significant history of chronic gastrointestinal disease including any uncorrected congenital malformation of the gastrointestinal tract, intussusception or other medical condition determined to be serious by the investigator.","healthyVolunteers":true,"sex":"ALL","minimumAge":"6 Weeks","maximumAge":"12 Weeks","stdAges":["CHILD"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Concentrations of Antibodies Against Vaccine Components of the Pneumococcal Vaccine","description":"Concentrations are given as Geometric Mean Concentrations (GMCs) in microgram per milliliter (μg/mL).\n\nVaccine pneumococcal serotypes assessed included 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.67","spread":null},{"groupId":"OG001","value":"2.46","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.95","spread":null},{"groupId":"OG001","value":"3.14","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.34","spread":null},{"groupId":"OG001","value":"3.59","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.31","spread":null},{"groupId":"OG001","value":"1.23","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.10","spread":null},{"groupId":"OG001","value":"3.20","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.34","spread":null},{"groupId":"OG001","value":"3.14","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.13","spread":null},{"groupId":"OG001","value":"4.74","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.00","spread":null},{"groupId":"OG001","value":"5.15","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.69","spread":null},{"groupId":"OG001","value":"6.96","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.98","spread":null},{"groupId":"OG001","value":"1.68","spread":null}]}]}]},{"type":"PRIMARY","title":"Concentration of Antibody Against Protein D (PD)","description":"Concentration was expressed as GMC in GSK's 22F enzyme-linked-immunosorbent assay (ELISA) units per milliliter (EL.U/mL).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2543.6","spread":null},{"groupId":"OG001","value":"1869.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Anti-pneumococcal Vaccine Serotype Antibody Concentrations Equal to or Above 0.20 µg/mL","description":"Vaccine pneumococcal serotypes included 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"219","spread":null},{"groupId":"OG001","value":"218","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"219","spread":null},{"groupId":"OG001","value":"218","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"218","spread":null},{"groupId":"OG001","value":"218","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"211","spread":null},{"groupId":"OG001","value":"204","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"218","spread":null},{"groupId":"OG001","value":"217","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"219","spread":null},{"groupId":"OG001","value":"218","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"218","spread":null},{"groupId":"OG001","value":"218","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"219","spread":null},{"groupId":"OG001","value":"217","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"218","spread":null},{"groupId":"OG001","value":"217","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"215","spread":null},{"groupId":"OG001","value":"212","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Anti-pneumococcal Cross-reactive Serotype Concentrations Equal to or Above 0.20 µg/mL","description":"Anti-pneumococcal cross-reactive serotypes were 6A and 19A.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"152","spread":null},{"groupId":"OG001","value":"132","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"135","spread":null},{"groupId":"OG001","value":"119","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Opsonophagocytic Activity Against Vaccine Pneumococcal Serotypes","description":"Vaccine pneumococcal serotypes included 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F, and 23F.\n\nOpsonophagocytic activity was defined as the dilution of serum (opsonic titer) able to sustain 50% killing of live pneumococci under the assay conditions. The cut-off of the assay was an opsonic titer equal to or greater than 8.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"185","spread":null},{"groupId":"OG001","value":"189","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"207","spread":null},{"groupId":"OG001","value":"203","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"204","spread":null},{"groupId":"OG001","value":"203","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"196","spread":null},{"groupId":"OG001","value":"191","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"206","spread":null},{"groupId":"OG001","value":"208","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"207","spread":null},{"groupId":"OG001","value":"208","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"208","spread":null},{"groupId":"OG001","value":"207","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"202","spread":null},{"groupId":"OG001","value":"199","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"202","spread":null},{"groupId":"OG001","value":"200","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"207","spread":null},{"groupId":"OG001","value":"206","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Opsonophagocytic Activity Against Cross-reactive Pneumococcal Serotypes","description":"Cross-reactive pneumococcal serotypes were 6A and 19A.\n\nOpsonophagocytic activity was defined as the dilution of serum (opsonic titer) able to sustain 50% killing of live pneumococci under the assay conditions. The cut-off of the assay was an opsonic titer equal to or greater than 8.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"173","spread":null},{"groupId":"OG001","value":"171","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"83","spread":null},{"groupId":"OG001","value":"75","spread":null}]}]}]},{"type":"SECONDARY","title":"Opsonophagocytic Titers of Cross-reactive Pneumococcal Serotypes","description":"Opsonophagocytic titers were expressed as GMTs.\n\nCross-reactive pneumococcal serotypes included 6A and 19A.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"230.8","spread":null},{"groupId":"OG001","value":"173.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"18.1","spread":null},{"groupId":"OG001","value":"15.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Poliovirus Types 1, 2 and 3 Titers","description":"Titers were given as Geometric Mean Titers (GMTs).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"313.8","spread":null},{"groupId":"OG001","value":"328.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"278.7","spread":null},{"groupId":"OG001","value":"229.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"408.8","spread":null},{"groupId":"OG001","value":"449.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Concentrations of Antibodies Against Diphteria Toxoid (DT) and Tetanus Toxoid (TT)","description":"Concentrations were defined as GMCs in international units per milliter (IU/mL)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.317","spread":null},{"groupId":"OG001","value":"3.353","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.879","spread":null},{"groupId":"OG001","value":"4.476","spread":null}]}]}]},{"type":"SECONDARY","title":"Concentration of Antibody Against Hepatitis B Surface Antigen (HBs) by Enzyme Linked ImmunoSorbent Assay (ELISA).","description":"Concentration was given as GMC in milli international units per milliliter (mIU/mL). As a decrease in the specificity of the anti-HB ELISA assay had been observed in some studies for low levels of antibody (10-100 mIU/mL), the table shows results following partial or complete reanalysis.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1521.2","spread":null},{"groupId":"OG001","value":"2114.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Concentration of Antibody Against Rotavirus Immunoglobulin A (IgA)","description":"Concentration was expressed as GMC in units per milliliter (U/mL).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"141.1","spread":null},{"groupId":"OG001","value":"114.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Occurrence of Serious Adverse Events","description":"SAEs assessed include medical occurrences that result in death, is life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"18","spread":null},{"groupId":"OG001","value":"7","spread":null}]}]}]},{"type":"SECONDARY","title":"Opsonophagocytic Titers of Vaccine Pneumococcal Serotypes","description":"Titers are presented as Geometric Mean Titers (GMTs).\n\nPneumococcal serotypes included 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"128.9","spread":null},{"groupId":"OG001","value":"122.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"698.3","spread":null},{"groupId":"OG001","value":"609.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"127.9","spread":null},{"groupId":"OG001","value":"98.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"870.7","spread":null},{"groupId":"OG001","value":"619.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3905.8","spread":null},{"groupId":"OG001","value":"3585.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1800.0","spread":null},{"groupId":"OG001","value":"1851.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1521.0","spread":null},{"groupId":"OG001","value":"1485.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"533.5","spread":null},{"groupId":"OG001","value":"383.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"689.6","spread":null},{"groupId":"OG001","value":"573.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2716.7","spread":null},{"groupId":"OG001","value":"2379.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Solicited Local and General Symptoms.","description":"Solicited local symptoms were pain, redness and swelling.\n\nSolicited general symptoms were drowsiness, fever, irritability, loss of appetite, diarrhoea and vomiting.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"162","spread":null},{"groupId":"OG001","value":"157","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"149","spread":null},{"groupId":"OG001","value":"142","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"133","spread":null},{"groupId":"OG001","value":"124","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"151","spread":null},{"groupId":"OG001","value":"136","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"193","spread":null},{"groupId":"OG001","value":"175","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"168","spread":null},{"groupId":"OG001","value":"171","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"127","spread":null},{"groupId":"OG001","value":"121","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"53","spread":null},{"groupId":"OG001","value":"54","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"44","spread":null},{"groupId":"OG001","value":"46","spread":null}]}]}]},{"type":"SECONDARY","title":"Concentrations of Antibodies Against Pertussis Toxoid (PT), Filamentous Haemagglutinin (FHA), Pertactin (PRN)","description":"Concentrations are expressed as GMCs in EL.U/mL.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"46.5","spread":null},{"groupId":"OG001","value":"45.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"179.2","spread":null},{"groupId":"OG001","value":"186.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"142.1","spread":null},{"groupId":"OG001","value":"128.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Concentration of Antibody Against Polyribosyl-ribitol Phosphate (PRP)","description":"Concentrain was expressed as GMC in µg/mL.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9.745","spread":null},{"groupId":"OG001","value":"6.387","spread":null}]}]}]},{"type":"SECONDARY","title":"Occurrence of Unsolicited Adverse Events","description":"An AE is any untoward medical occurrence in a clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"88","spread":null},{"groupId":"OG001","value":"96","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":18,"n":233},"commonTop":["Fever","Irritability","Pain","Redness","Drowsiness"]}}}